RNAimmune has a total of 31 patents globally. Of these 31 patents, more than 87% patents are active. The United States of America is where RNAimmune has filed the maximum number of patents, followed by Singapore and China. Parallelly, The United States of America seems to be the main focused R&D center and also USA is the origin country of RNAimmune.
RNAimmune was founded in the year 2020. RNAimmune, a biotechnology startup specializing in messenger RNA (mRNA) technology, boasts over two decades of experience in manipulating and enhancing this adaptable molecule for therapeutic applications. Central to RNAimmune’s unique approach is leveraging mRNA as a conduit to prompt the body to generate specific proteins, empowering it to combat various diseases effectively.
Do read about some of the most popular patents of RNAimmune which have been covered by us in this article and also you can find RNAimmune patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over RNAimmune patent portfolio.
How many patents does RNAimmune have?
RNAimmune has a total of 31 patents globally. These patents belong to 6 unique patent families. Out of 31 patents, 27 patents are active.
How Many Patents did RNAimmune File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | RNAimmune Applications Filed | RNAimmune Patents Granted |
| 2023 | 3 | – |
| 2022 | 8 | – |
| 2021 | 20 | – |
How many RNAimmune patents are Alive/Dead?
Worldwide Patents
How Many Patents did RNAimmune File in Different Countries?
Countries in which RNAimmune Filed Patents
| Country | Patents |
| United States Of America | 3 |
| China | 2 |
| Singapore | 2 |
| New Zealand | 2 |
| Europe (EPO) | 2 |
| Taiwan | 2 |
| Canada | 2 |
| Australia | 2 |
| Israel | 2 |
| Japan | 2 |
| Hong Kong (S.A.R.) | 1 |
| Brazil | 1 |
| South Africa | 1 |
| Mexico | 1 |
Where are Research Centers of RNAimmune Patents Located?
The Research Centre for all the RNAimmune patents is the United States of America.
Best RNAimmune Patents
US20220040292A1 is the most popular patent in the RNAimmune portfolio. It has received 3 citations so far from companies like BioNTech.
List of RNAimmune Patents
| RNAimmune Patents | Title |
| US20230355527A1 | Compounds And Compositions For Drug Delivery |
| US20230108926A1 | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
| US20220040292A1 | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
| EP4228679A1 | Pan-Ras Mrna Cancer Vaccines |
| EP4100066A2 | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
| CN116917470A | Pan-Ras Mrna Cancer Vaccine |
| CN115297892A | Compositions And Methods Of Mrna Vaccines Against Novel Coronavirus Infection |
| JP2023546133A | Pan-Ras Mrna Cancer Vaccine |
| WO2023196615A1 | Compounds And Compositions For Drug Delivery |
| WO2023091766A3 | Compositions And Methods Of Ribonucleic Acid Respiratory Syncytial Virus (Rsv) Vaccines |
| TW202330922A | Compositions And Methods Of Ribonucleic Acid Respiratory Syncytial Virus (Rsv) Vaccines |
| TW202328166A | Composition And Methods Of Mrna Vaccines Against Novel Coronavirus Infection |
| AU2021360796A1 | Pan-Ras Mrna Cancer Vaccines |
| IL302065A | Pan-Ras Mrna Cancer Vaccines |
| SG11202302776TA | Pan-Ras Mrna Cancer Vaccines |
| JP2023512833A | Compositions And Methods Of Mrna Vaccine Against Novel Coronavirus Infection |
| WO2023018831A9 | Composition And Methods Of Mrna Vaccines Against Novel Coronavirus Infection |
| SG11202300704XA | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
| CA3222139A1 | Multiplexed Tp53 And Pan-Ras Mrna Cancer Vaccines |
| IL295360A | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
| AU2021216443A1 | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
| NZ799236A | Pan-Ras Mrna Cancer Vaccines |
| NZ791151A | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
| CA3167257A1 | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
| HK40078180A | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
| MX2022009688A | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection. |
| BR112022015626A2 | Composition And Methods Of Mrna Vaccines Against New Coronavirus Infection |
| WO2022261514A3 | Multiplexed Tp53 And Pan-Ras Mrna Cancer Vaccines |
| WO2021159118A8 | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
| WO2022081764A1 | Pan-Ras Mrna Cancer Vaccines |
| ZA202209695A | Composition And Method Of Mrna Vaccines Against Novel Coronavirus Infection |
What are RNAimmune key innovation segments?
What Technologies are Covered by RNAimmune?
The chart below distributes patents filed by RNAimmune in different countries on the basis of the technology protected in patents. It also represents the markets where RNAimmune thinks it’s important to protect particular technology inventions.
R&D Focus: How has RNAimmune search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!